An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)
Phase of Trial: Phase II
Latest Information Update: 18 May 2018
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions
- Acronyms PIONEER-OLE
- Sponsors MyoKardia
- 10 May 2018 According to a MyoKardia media release, first interim data are expected in the first quarter of 2019.
- 10 May 2018 Status changed from not yet recruiting to recruiting, according to a MyoKardia media release.
- 07 May 2018 Planned number of patients changed from 20 to 12.